Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms

15Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The seasonal influenza A vaccine is recommended for patients with myeloproliferative neoplasms (MPNs). We hypothesised that immune deregulation associated with MPNs may affect the immune response gained following vaccinations when compared to healthy controls. Using deep immunophenotyping with high-dimensional single-cell analysis and mass cytometry we could demonstrate an altered immune response in MPN patients following vaccination. We found that prior to vaccination, MPN patients had reduced numbers of naive CD4 T cells. Furthermore, at 3-weeks and 3-months post-vaccination there was evidence of both delayed and impaired B- and T-memory cells responses. Thus, although, the immune systems of MPN patients can 'recognise' the Influenza A vaccine, the response appears inferior compared to healthy controls.

Cite

CITATION STYLE

APA

Alimam, S., Ann Timms, J., Harrison, C. N., Dillon, R., Mare, T., DeLavallade, H., … McLornan, D. P. (2021). Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology, 193(1), 150–154. https://doi.org/10.1111/bjh.17096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free